S&P 500   4,298.30 (-0.03%)
DOW   33,563.55 (-0.31%)
QQQ   360.05 (+0.57%)
AAPL   171.70 (+0.59%)
MSFT   317.94 (+1.37%)
META   304.76 (+0.26%)
GOOGL   131.87 (-0.33%)
AMZN   127.76 (+1.41%)
TSLA   251.87 (+2.23%)
NVDA   436.98 (+1.41%)
NIO   9.04 (+1.46%)
BABA   87.04 (+1.75%)
AMD   104.07 (+1.27%)
T   15.00 (-0.07%)
F   12.54 (-0.16%)
MU   68.05 (+4.37%)
CGC   0.80 (-1.19%)
GE   110.46 (-1.67%)
DIS   80.89 (+0.95%)
AMC   8.06 (+3.47%)
PFE   33.02 (+2.90%)
PYPL   58.63 (+0.77%)
NFLX   377.72 (+0.36%)
S&P 500   4,298.30 (-0.03%)
DOW   33,563.55 (-0.31%)
QQQ   360.05 (+0.57%)
AAPL   171.70 (+0.59%)
MSFT   317.94 (+1.37%)
META   304.76 (+0.26%)
GOOGL   131.87 (-0.33%)
AMZN   127.76 (+1.41%)
TSLA   251.87 (+2.23%)
NVDA   436.98 (+1.41%)
NIO   9.04 (+1.46%)
BABA   87.04 (+1.75%)
AMD   104.07 (+1.27%)
T   15.00 (-0.07%)
F   12.54 (-0.16%)
MU   68.05 (+4.37%)
CGC   0.80 (-1.19%)
GE   110.46 (-1.67%)
DIS   80.89 (+0.95%)
AMC   8.06 (+3.47%)
PFE   33.02 (+2.90%)
PYPL   58.63 (+0.77%)
NFLX   377.72 (+0.36%)
S&P 500   4,298.30 (-0.03%)
DOW   33,563.55 (-0.31%)
QQQ   360.05 (+0.57%)
AAPL   171.70 (+0.59%)
MSFT   317.94 (+1.37%)
META   304.76 (+0.26%)
GOOGL   131.87 (-0.33%)
AMZN   127.76 (+1.41%)
TSLA   251.87 (+2.23%)
NVDA   436.98 (+1.41%)
NIO   9.04 (+1.46%)
BABA   87.04 (+1.75%)
AMD   104.07 (+1.27%)
T   15.00 (-0.07%)
F   12.54 (-0.16%)
MU   68.05 (+4.37%)
CGC   0.80 (-1.19%)
GE   110.46 (-1.67%)
DIS   80.89 (+0.95%)
AMC   8.06 (+3.47%)
PFE   33.02 (+2.90%)
PYPL   58.63 (+0.77%)
NFLX   377.72 (+0.36%)
S&P 500   4,298.30 (-0.03%)
DOW   33,563.55 (-0.31%)
QQQ   360.05 (+0.57%)
AAPL   171.70 (+0.59%)
MSFT   317.94 (+1.37%)
META   304.76 (+0.26%)
GOOGL   131.87 (-0.33%)
AMZN   127.76 (+1.41%)
TSLA   251.87 (+2.23%)
NVDA   436.98 (+1.41%)
NIO   9.04 (+1.46%)
BABA   87.04 (+1.75%)
AMD   104.07 (+1.27%)
T   15.00 (-0.07%)
F   12.54 (-0.16%)
MU   68.05 (+4.37%)
CGC   0.80 (-1.19%)
GE   110.46 (-1.67%)
DIS   80.89 (+0.95%)
AMC   8.06 (+3.47%)
PFE   33.02 (+2.90%)
PYPL   58.63 (+0.77%)
NFLX   377.72 (+0.36%)
NASDAQ:MDRX

Veradigm (MDRX) Stock Forecast, Price & News

$13.26
-0.12 (-0.90%)
(As of 12:32 PM ET)
Compare
Today's Range
$13.11
$13.39
50-Day Range
$12.19
$13.76
52-Week Range
$11.30
$19.77
Volume
257,876 shs
Average Volume
1.02 million shs
Market Capitalization
$1.45 billion
P/E Ratio
30.84
Dividend Yield
N/A
Price Target
$19.36

Veradigm MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
45.7% Upside
$19.36 Price Target
Short Interest
Bearish
8.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
1.06mentions of Veradigm in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-10.17%
From $0.59 to $0.53 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Business Services Sector

209th out of 322 stocks

Computer Integrated Systems Design Industry

27th out of 38 stocks


MDRX stock logo

About Veradigm (NASDAQ:MDRX) Stock

Veradigm Inc., a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates through two segments, Hospitals and Large Physician Practices, and Veradigm. The Hospitals and Large Physician Practices segment provides integrated clinical and financial management solutions, which primarily include EHR-related software; and related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Veradigm segment offers payer and life sciences solutions, which are primarily targeted at payers, life sciences companies, and other healthcare stakeholders; and software applications for patient engagement and EHR software to single-specialty, and small and mid-sized physician practices, including related clinical, financial, administrative, and operational solutions. Its solutions enable clients to transition, analyze, and coordinate care, and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments and militaries, health systems, health plans, life-sciences companies, retail clinics, surgery centers, retail pharmacies, pharmacy benefit managers, insurance companies, employer wellness clinics, consumers, lab companies, urgent care facilities, and venture capital firms, as well as post-acute organizations, such as home health and hospice agencies. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

MDRX Price History

MDRX Stock News Headlines

Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
Veradigm: Some Promise Combined With Uncertainty
Veradigm (NASDAQ:MDRX) vs. Kyndryl (NYSE:KD) Head-To-Head Contrast
Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
RBC Capital Reaffirms Their Buy Rating on Veradigm (MDRX)
MDRX - Allscripts Healthcare Solutions, Inc.
MDRX - Veradigm Inc.
Veradigm Increasing Presence in Payer Market
See More Headlines
Receive MDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veradigm and its competitors with MarketBeat's FREE daily newsletter.

MDRX Company Calendar

Last Earnings
11/04/2021
Today
9/29/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Computer integrated systems design
Sub-Industry
Health Care Technology
Current Symbol
NASDAQ:MDRX
CUSIP
01988P10
Employees
8,000
Year Founded
1986

Price Target and Rating

Average Stock Price Forecast
$19.36
High Stock Price Forecast
$26.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+44.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.50 billion
Cash Flow
$2.90 per share
Book Value
$11.49 per share

Miscellaneous

Free Float
106,758,000
Market Cap
$1.46 billion
Optionable
Optionable
Beta
0.93

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Richard J. PoultonMr. Richard J. Poulton (Age 58)
    CEO & Director
    Comp: $2.45M
  • Ms. Tejal Vakharia (Age 49)
    Sr. VP of Marketing & Gov. Affairs, Gen. Counsel and Chief Compliance Counsel
    Comp: $1.04M
  • Mr. Thomas J. Langan (Age 57)
    Pres & CCO
  • Ms. Leah Jones (Age 50)
    Chief Financial Officer
  • Mr. Joseph R. Rostock (Age 60)
    Sr. VP of Devel. & CTO
  • Jenny Gelinas
    VP of Investor Relations
  • Mr. Richard Elmore
    Sr. VP of Corp. Devel. & Strategy
  • Ms. Lisa Hammond C.P.C. (Age 50)
    Sr. VP & Chief HR Officer
  • Mr. John Sage
    Sr. VP of U.S. Hospitals & Health Systems Sales
  • Mr. Elliot Bryant
    Sr. VP & Gen. Mang. for Classic Client Solutions Bus. Unit













MDRX Stock - Frequently Asked Questions

Should I buy or sell Veradigm stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veradigm in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" MDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MDRX, but not buy additional shares or sell existing shares.
View MDRX analyst ratings
or view top-rated stocks.

What is Veradigm's stock price forecast for 2023?

5 equities research analysts have issued 12 month target prices for Veradigm's stock. Their MDRX share price forecasts range from $13.00 to $26.00. On average, they expect the company's stock price to reach $19.36 in the next year. This suggests a possible upside of 44.7% from the stock's current price.
View analysts price targets for MDRX
or view top-rated stocks among Wall Street analysts.

How have MDRX shares performed in 2023?

Veradigm's stock was trading at $17.64 at the beginning of 2023. Since then, MDRX stock has decreased by 24.1% and is now trading at $13.38.
View the best growth stocks for 2023 here
.

How were Veradigm's earnings last quarter?

Veradigm Inc. (NASDAQ:MDRX) released its quarterly earnings data on Thursday, November, 4th. The software maker reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.09. The software maker earned $369 million during the quarter, compared to the consensus estimate of $376.09 million. The business's revenue was down 8.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.15 EPS.

What ETFs hold Veradigm's stock?
What guidance has Veradigm issued on next quarter's earnings?

Veradigm issued an update on its FY 2023 earnings guidance on Monday, September, 18th. The company provided EPS guidance of $0.80-$0.90 for the period, compared to the consensus EPS estimate of $0.87. The company issued revenue guidance of $615.00 million-$635.00 million, compared to the consensus revenue estimate of $638.08 million.

What is Paul Black's approval rating as Veradigm's CEO?

796 employees have rated Veradigm Chief Executive Officer Paul Black on Glassdoor.com. Paul Black has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Veradigm own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veradigm investors own include Advanced Micro Devices (AMD), Netflix (NFLX), Energy Transfer (ET), CVS Health (CVS), Ford Motor (F), Himax Technologies (HIMX), Intel (INTC), OPKO Health (OPK), Tesla (TSLA) and Activision Blizzard (ATVI).

What is Veradigm's stock symbol?

Veradigm trades on the NASDAQ under the ticker symbol "MDRX."

How do I buy shares of Veradigm?

Shares of MDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veradigm's stock price today?

One share of MDRX stock can currently be purchased for approximately $13.38.

How much money does Veradigm make?

Veradigm (NASDAQ:MDRX) has a market capitalization of $1.46 billion and generates $1.50 billion in revenue each year. The software maker earns $134.44 million in net income (profit) each year or $0.43 on an earnings per share basis.

How many employees does Veradigm have?

The company employs 8,000 workers across the globe.

Does Veradigm have any subsidiaries?
The following companies are subsidiares of Veradigm: HealthGrid, Practice Fusion, and ZappRx.
Read More
How can I contact Veradigm?

Veradigm's mailing address is 222 MERCHANDISE MART PLAZA SUITE 2024, CHICAGO IL, 60654. The official website for the company is www.allscripts.com. The software maker can be reached via phone at (800) 334-8534, via email at stephen.shulstein@allscripts.com, or via fax at 313-322-9600.

This page (NASDAQ:MDRX) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -